Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2004-02-12
2011-10-18
Audet, Maury (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C530S327000, C530S300000, C514S019200, C424S001690
Reexamination Certificate
active
08039585
ABSTRACT:
Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.
REFERENCES:
patent: 6121236 (2000-09-01), Ben-Sasson
patent: 6667388 (2003-12-01), Bein et al.
Ciulla, T.A. 2003. Recent advances in the treatment of exudative age-related macular degeneration, including transpupillary thermotherapy. Acta Opthalmol Scand 81:103-104.
Grant, D.S., et al. 1989. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58:933-943.
Iwamoto, Y., et al. 1987. YIGSR a pentapeptide from the B1 chain of laminin inhibits tumor cell metastases. Science 238:1132-1134.
Kuratomi, Y., et al. 2002. Laminin γ1 chain peptide, C-16 (KAFDITYVRLKF), promotes migration, MMP-9 secretion, and pulmonary metastasis of B16-F10 mouse melanoma cells. Br J Cancer 86:1169-1173.
Kuratomi, Y., et al. 1999. Identification of metastasis-promoting sequences in the mouse laminin α-1 chain. Exp Cell Res 249:386-395.
Malinda, K. M., et al. 1999. Identification of laminin α-1 and β-1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. FASEB J 13:53-62.
Ponce, M. L., et al. 1999. Identification of endothelial cell binding sites on the laminin γ-1 chain. Circ Res 84:688-694.
Ponce, M. L., Nomizu, M., Kleinman, H. K. 2001. An angiogenic laminin site and its antagonist bind through the αvβ3 and α5β1 integrins. FASEB J 15:1389-1397.
Ponce, M. L., Kleinman, H. K. 2003a. Identification of Redundant Angiogenic sites in laminin α1 and γ1 chains. Exp Cell Res 285:189-195.
Ponce, M.L., et al. 2003b. Identification of a potent peptide antagonist to an active laminin-1 sequence that blocks angiogenesis and tumor growth. Cancer Res 63:5060-5064.
Powell, S.K., Kleinman, H.K. 1997. Neuronal laminins and their cellular receptors. Int J Biochem Cell Biol 29:401-414.
Pupa, S.M., Menard, S., Forti, S., Tagliabue, E. 2002. New insights into the role of extracellular matrix during tumor onset and progression. J Cellul Physiol 192:259-267.
Sakamoto, N., Iwahana, M., Tanaka, N.G., Osada, Y. 1991. Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CD PGYIGSR-NH2. Cancer Res 51:903-906.
Varner, J.A., Cheresh, D.A. 1996. Tumor angiogenesis and the role of vascular cell integrin α v β3. Important Adv Oncol 69-87.
Auerbach, R. et al., “Expression of Organ-Specific Antigens on Capillary Endothelial Cells,” Microvascular Research, no month available, 1985, 29:401-411.
Brooks, P. et al., “Requirement of Vascular Integrin αvβ3for Angiogenesis,” Science (Wash DC), Apr. 22, 1994, 264:569-571.
Burgeson, R. et al., “A New Nomenclature for the Laminins,” Matrix Biology, No month available, 1994, 14:209-211.
C-elegans Sequencing Consortium, “Genome Sequence of the Nematode C.elegans: A Platform for Investigating Biology,” Science, Dec. 11, 1998, 282(5369), 2012-2018.
Colognato, H. et al, “Form and Function: The Laminin Family of Heterotrimers,” Developmental Dynamics, no month available, 2000, 218:213-234.
Fisher, C. et al., “Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein,” The Soluble TNF Receptor Sepsis Study Group, New England Journal of Medicine, Jun. 27, 1996, 334(26):1697-1702.
Folkman, J., “Angiogenesis in Cancer, Vascular, Rheumatoid and Other Diseases,” Nature Medicine, no month available, Jan. 1995, 1(1):27-31.
Francis, G., “Protein Modification and Fusion Proteins,” Focus on Growth Factors, no month available, 1992, 3:4-10.
Fridman, R. et al., “Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines,” Proc Natl Acad Sci USA, Sep. 1990, 87:6698-6702.
Friedlander, M. et al., “Definition of Two Angiogenic Pathways by Distinct αvIntegrins,” Science, (Wash DC), Dec. 1, 1995, 270:1500-1502.
Fujihara, S. et al. “A D-Amino Acid Peptide Inhibitor of NF-κB Nuclear Localization Is Efficacious in Models of Inflammatory Disease,” no month available, Journal of Immunology, 2000, 165:1004-1012.
Gho, Y. et al., “Angiogenic Activity of Human Soluble Intercellular Adhesion Molecule-1,” Cancer Research, Oct. 15, 1999, 59:5128-5132.
Gho, Y. et al., “Stimulation of Tumor Growth by Human Soluble Intercellular Adhesion Molecule-1,” Cancer Research, May 15, 2001, 61:4253-4257.
Harvill, E. et al., “An IgG3-IL2 fusion protein activates complement, binds FcγRI, generates LAK activity and shows enhanced binding to the high affinity IL-2R,” Immunotechnology, May 1995, 1(2):95-105.
Iivanainen, E. et al., “Endothelial Cell Matrix Interactions,” Microscopy Research and Technology, no month available, 2003, 60:13-22.
Jaffe, E. et al., “Culture of Human Endothelial Cells Derived from Umbilical Veins. Identification By Morphologic and Immunologic Criteria,” Journal of Clinical Investigation, Nov. 1973, 52:2745-2756.
Kleinman, H. et al., “Role of Basement Membrane in Tumor Growth and Metastasis,” Surgical Oncology Clinics of North America, Apr. 2001, 10(2), 329-338.
Kubota, Y. et al., “Role of Laminin and Basement Membane in the Morphological Differentiation of Human Endothelial Cells into Capillary-like Structures,” J Cell Biol, Oct. 1988, 107:1589-1597.
Lehoux, S. et al., “Cellular mechanics and gene expression in blood vessels,” J Biomech, 2003, 36:631-643.
Maeshima, Y. et al., “Extracellular Matrix-derived Peptide Binds to αvβ3Integrin and Inhibits Angiogenesis,” Journal of Biol Chem, Aug. 24, 2001, 276(34):31959-31968.
Miner, J. et al., “The Laminin α Chains: Expression, Developmental Transitions, and Chromosomal Locations of α1-5, Identification of Heterotrimeric Laminins 8-11, and Cloning of a Novel α3 Isoform,” Journal of Cell Biol, May 5, 1997, 137(3):685-701.
Nomizu, M. et al., “Identification of Cell Binding Sites in the Laminin α1 Chain Carboxyl-terminal Globular Domain by Systematic Screening of Synthetic Peptides,” Journal of Biol Chem, Sep. 1, 1995, 270(35):20583-20590.
Nomizu, M. et al., “Identification of cell binding sequences in mouse laminin y-1 chain by systematic peptide screening,” Journal of Biol Chem, 1997, 272:32198-32205.
Nomizu, M. et al., “Cell Binding Sequences in Mouse Laminin α1 chain,” J Biol Chem, Dec. 4, 1998, 273(46):32491-32499.
Nomizu, M. et al., “Identification of Homologous Biologically Active Sites on the N-Terminal Domain of Laminin Alpha Chains,” Biochemistry, No month available, 2001, 40(50):15310-15317.
O'Reilly, M. et al., “Angiostatin: A Novel Angiogenesis Inhibitor That Mediates The Suppression of Metastases By a Lewis Lung Carcinoma,” Cell, Oct. 21, 1994, 79:315-328.
O'Reilly, M. et al., “Endostatin: An Endogenous Inhibitor Of Angiogenesis and Tumor Growth,” Cell, Jan. 24, 1997, 24(88):277-285.
Pepper, M
Csaky Karl G.
Kleinman Hynda
Ponce Lourdes
Audet Maury
The United States of America as represented by the Department of
Woodcock & Washburn LLP
LandOfFree
Therapeutic administration of the scrambled anti-angiogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic administration of the scrambled anti-angiogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic administration of the scrambled anti-angiogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4276936